en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2020
vol. 95
 
Share:
Share:
Case report

Acute liver failure due to previously unrecognised dilated cardiomyopathy in a 17-year-old boy with Duchenne muscular dystrophy

Kamil Janowski
1
,
Lidia Ziółkowska
2
,
Agnieszka Boruc
2
,
Katarzyna Witulska
3
,
Maria Janowska
4
,
Marek Stefanowicz
4
,
Wioletta Jarmużek
5
,
Joanna Pawłowska
1

  1. Department of Gastroenterology, Hepatology, Nutritional Disorders, and Paediatrics, The Children’s Memorial Health Institute, Warsaw, Poland
  2. Department of Cardiology, The Children’s Memorial Health Institute, Warsaw, Poland
  3. Department of Anaesthesiology, The Children’s Memorial Health Institute, Warsaw, Poland
  4. Department of Paediatric Surgery and Organ Transplantation, The Children’s Memorial Health Institute, Warsaw, Poland
  5. Department of Nephrology, The Children’s Memorial Health Institute, Warsaw, Poland
Pediatr Pol 2020; 95 (3): 178–183
Online publish date: 2020/10/30
Article file
- Acute liver failure.pdf  [1.22 MB]
Get citation
 
PlumX metrics:
 
1. Correale M, Tarantino N, Petrucci R, et al. Liver disease and heart failure: Back and forth. Eur J Intern Med 2018; 48: 25-34.
2. Scarpati G, De Robertis E, Esposito C, Piazza O. Hepatic encephalopathy and cirrhotic cardiomyopathy in Intensive Care Unit. Minerva Anestesiol 2018; 84: 970-979.
3. Saner FH, Heuer M, Meyer M, et al. When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res 2009; 14: 541-546.
4. Fussell KM, Awad JA, Ware LB. Case of fulminant hepatic failure due to unrecognized peripartum cardiomyopathy. Crit Care Med 2005; 33: 891-893.
5. Wagle K, Akinseye OA, Shrestha P, et al. A Case of Fulminant Hepatic Failure Secondary to Congestive Heart Failure Without Evidence of Acute Cardiac Decompensation. S D Med 2017; 70: 155-159.
6. Kaymakcalan H, Dourdourekas D, Szanto PB, Steigmann F. Congestive heart failure as cause of fulminant hepatic failure. Am J Med 1978; 65: 384-388.
7. Kisloff B, Schaffer G. Fulminant hepatic failure secondary to congestive heart failure. Am J Dig Dis 1976; 21: 895-900.
8. Wiesen S, Reddy KR, Jeffers LJ, Schiff ER. Fulminant hepatic failure secondary to previously unrecognized cardiomyopathy. Dig Dis 1995; 13: 199-204.
9. Karasek D, Sinkiewicz W. Problemy kardiologiczne chorych z dystrofiami nerwowo-mięśniowymi. Kardiol Dypl 2012; 11: 32-36.
10. Schade van Westrum SM, Hoogerwaard EM, Dekker L, et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology 2011; 77: 62-66.
11. Thrush PT, Allen HD, Viollet L, et al. Re-examination of the electrocardiogram in boys with Duchenne muscular dystrophy and correlation with its dilated cardiomyopathy. Am J Cardiol 2009; 103: 262-265.
12. Bourke JP, Watson G, Muntoni F, et al. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study. BMJ Open 2018; 8: e022572.
13. Doing AH, Renlund DG, Smith RA. Becker muscular dystrophy-related cardiomyopathy: A favorable response to medical therapy. J Heart Lung Transplant 2002; 21: 496-498.
14. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003; 13: 166-172.
15. Rhodes J, Margossian R, Darras BT, et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008; 29: 343-351.
16. Viollet L, Thrush PT, Flanigan KM, et al. Effects of angiotensin converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012; 110: 98-102.
17. Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006; 70: 991-994.
18. Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009; 53: 72-78.
19. Fairclough RJ, Bareja A, Davies KE. Progress in therapy for Duchenne muscular dystrophy. Exp Physiol 2011; 96: 1101-1113.
20. Sun G, Haginoya K, Dai H, et al. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J Neurol Sci 2009; 280: 40-48.
21. McNally EM, Kaltman JR, Benson DW, et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation 2015; 131: 1590-1598.
22. Kwiatkowska J, Meyer-Szary J, Bazgier M, et al. Left ventricular volumes and function affected by myocardial fibrosis in patients with Duchenne and Becker muscular dystrophies: a preliminary magnetic resonance study. Kardiol Pol 2020; 78: 331-334.
23. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018; 17: 251-267.
24. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018; 17: 347-361.
25. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 2018; 17: 445-455.
26. https://treat-nmd.org/family-care-guide/english-uk-dmd/
Copyright: © 2020 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.